Akışa dön
75/100 Bearish 08.09.2026 · 06:05 Finrend AI ⏱ 1 dk 👁 42 TR

Novartis shares fall after second pipeline setback this week

Shares of Swiss pharmaceutical giant Novartis fell sharply following the second pipeline failure this week. Negative developments regarding the company's drug candidates in development shook investor confidence and adversely affected share performance. According to Reuters, this latest setback occurred because one of the potential blockbuster candidates in Novartis' research and development portfolio failed to deliver expected results in clinical trials or encountered a regulatory hurdle. The company faced a similar pipeline issue earlier this week. Such pipeline failures represent a significant risk factor for pharmaceutical companies, as the return on large investments in R&D processes depends on these candidates reaching the commercialization stage. The consecutive setbacks experienced by Novartis have heightened concerns about the company's medium- and long-term growth prospects. Market analysts suggest that these developments could pressure Novartis' share valuation and may necessitate a revision of projections for future drug revenues. Investors are closely monitoring whether the company will take new strategic steps to offset these losses and the status of other pipeline projects. This is not investment advice.

📊 NVS — Piyasa Yorumu

▼ down · 60%

The headline indicates that Novartis has encountered a second setback in its pipeline, leading to a drop in shares. Such consecutive negative developments could undermine investor confidence and create selling pressure in the short term. Technical indicators also point to weakness: the price is below the 20-day moving average, and the RSI is below 50, suggesting negative momentum. The MACD remains below the signal line, confirming a downward short-term trend. However, the decline is expected to be limited, as the 50-day average may still provide support, and the impact of the news could fade within a few days.

RSI 14
47.4
MACD
0.31
24h Δ
-1.00%

📊 GOOGL — Piyasa Yorumu

▼ down · 30%

Although the news headline focuses on Novartis shares, it is not a direct catalyst for GOOGL, and any sector-wide spillover effect may remain limited. Technical indicators present a weak outlook: the price is below the SMA20 and SMA50, and the MACD is in negative territory and below its signal line. The RSI at 46 is in neutral territory, but momentum suggests a downward bias. In the short term, a sideways to slightly bearish trend can be expected, though there is no strong sell signal. Therefore, while the direction is bearish, the confidence level is kept low.

RSI 14
46.3
MACD
-0.18
24h Δ
1.27%
Canlı Grafikler

🔗 İlgili haberler

🧬 Buna benzer

AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.